Handelsavisen
prelaunch
Companies Healthcare 004720.KS
00
004720.KS KRX Pharmaceuticals

004720.Ks

$3 305,00
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
-73,6 %
ROE
-79,7 %
Net margin
-67,4 %
Debt / equity
0,04
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of prescription drugs and related healthcare products.

Business. The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of prescription drugs and related healthcare products.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-79,7 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 004720.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 004720.KS. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of prescription drugs and related healthcare products.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    The company's capital structure is characterized by a low debt-to-equity ratio of 0.04, indicating a conservative leverage position relative to its equity base. With total equity of KRW 146.3 billion and total liabilities of KRW 49.1 billion, the firm maintains a strong balance sheet. The current ratio of 2.85 suggests the company has sufficient short-term assets to cover its short-term liabilities. However, the free cash flow of -KRW 114.8 billion indicates a significant outflow of cash, which may be due to high capital expenditures or operational inefficiencies.

    Profitability metrics show a challenging performance, with a return on equity of -79.74% and a return on assets of -59.7%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets. The operating income is negative at -KRW 127.3 billion, and the net income is also negative at -KRW 116.7 billion, reflecting a significant loss for the period. These results are below the industry median for profitability metrics, suggesting the company is underperforming relative to its peers.

    The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no significant geographic diversification reported. This lack of diversification may expose the company to higher risks if market conditions in its primary market deteriorate. The absence of detailed segment or geographic breakdown in the provided data limits the ability to assess the extent of revenue concentration.

    The company's growth trajectory is uncertain, with no specific numeric deltas provided for the current or next fiscal year. The negative net income and operating income suggest a decline in performance, which may impact future growth prospects. The capital expenditure of -KRW 2.67 billion indicates some investment in long-term assets, but the overall financial performance suggests that the company may need to reassess its growth strategies.

    Risk factors include a low liquidity risk, as the company has sufficient cash and equivalents of KRW 21.9 billion to cover short-term obligations. However, the negative free cash flow and high operating losses may pose challenges in maintaining liquidity in the long term. The dilution risk is also low, with no immediate filing-based flags detected. The company's conservative debt structure and strong equity position provide some buffer against dilution pressures.

    Recent events, as disclosed in the financial statements, include a significant operating loss and a negative net income. These results may be attributed to increased costs or reduced revenue. The company has not disclosed any major events or strategic initiatives in the provided data, which limits the ability to assess recent developments that may impact its performance.

    Key takeaways
    • The company has a conservative capital structure with a low debt-to-equity ratio of 0.04.
    • Profitability is severely underperforming, with a return on equity of -79.74% and a return on assets of -59.7%.
    • The company's financial performance is marked by significant operating and net losses, indicating a challenging business environment.
    • The company has sufficient liquidity to cover short-term obligations, but the negative free cash flow may impact long-term sustainability.
    • There is no immediate dilution risk, but the company's financial performance may require strategic reassessment to ensure long-term growth.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $3 305,00
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $146.30B
    Net cash
    $15.88B
    Current ratio
    2.9
    Debt / equity
    0.0
    ROA
    -59.7%
    ROE
    -79.7%
    Cash conversion
    -5.0%
    CapEx / revenue
    -1.5%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-73,6 %Bottom quartile
    Net Margin-67,4 %Bottom quartile
    ROE-79,7 %Bottom quartile
    Capex / Rev-1,5 %Above P75
    D/E0,04Above median
    Cash Conv-0,05Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • 004720.KS Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    004720.KSCanonical
    KRX · USD

    Intel & risk

    What changed

    4 tracked-field change(s) detected vs prior analysis; max severity: medium.

    • Dilution risk— → lowlow
    • Liquidity risk— → lowlow
    • Activity— → Pharmaceuticals & Medical Researchmedium
    • Economic sector— → Healthcaremedium
    vs prior analysis today
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage